


**Amendments to the Claims:**

The following listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Original) A T-type calcium channel blocker that is optically active 1,4-dihydropyridine compound, a pharmaceutically acceptable salt thereof or a solvate thereof, of formula (1)



[wherein

$R^1$  and  $R^2$  are independently of each other  $C_{1-6}$  alkyl group {the  $C_{1-6}$  alkyl group may be substituted with phenyl group (the phenyl group may be substituted with  $C_{1-6}$  alkoxy group or halogen atom),  $C_{2-6}$  alkenyl group or  $C_{2-6}$  alkynyl group (the  $C_{2-6}$  alkenyl group and  $C_{2-6}$  alkynyl group may be substituted with phenyl group (the phenyl group may be substituted with  $C_{1-6}$  alkoxy group or halogen atom))}, or  $-L^1-NR^3R^4$  { $R^3$  and  $R^4$  are independently of each other  $C_{1-6}$  alkyl group (the  $C_{1-6}$  alkyl group may be substituted with phenyl group (the phenyl group may be substituted with  $C_{1-6}$  alkoxy group or halogen atom)) or phenyl group (wherein the phenyl group may be substituted with  $C_{1-6}$  alkoxy group or halogen atom),  $L^1$  is  $C_{2-6}$  alkylene group (the  $C_{2-6}$  alkylene group may be substituted with  $C_{1-3}$  alkyl group or phenyl group (the phenyl group may be arbitrarily substituted with halogen atom,  $C_{1-3}$  alkyl group or  $C_{1-3}$  alkoxy group))}, or

$R^1$  and  $R^2$  together form  $-CR^5R^6-CR^7R^8-$ ,  $-CR^5R^6-CR^7R^8-CR^9R^{10}-$  or  $-CR^5R^6-CR^7R^8-CR^9R^{10}-CR^{11}R^{12}-$  ( $R^5$  to  $R^{12}$  are independently of each other hydrogen atom or  $C_{1-6}$  alkyl

group, or any two of them together with the carbon atom bonding them may form 5-, 6- or 7-membered ring);


$X^1$  and  $X^2$  are independently of each other O or  $NR^{13}$  ( $R^{13}$  is hydrogen atom or  $C_{1-6}$  alkyl group);

Ar is phenyl group, pyridyl group, furyl group or 2,1,3-benzoxadiazol-4-yl group {the phenyl group, pyridyl group, furyl group and 2,1,3-benzoxadiazol-4-yl group may arbitrarily substituted with one or two substituents selected from  $NO_2$ ,  $CF_3$ , Br, Cl, F, R (R is  $C_{1-20}$  alkyl group), OH,  $OR^{14}$  ( $R^{14}$  is  $C_{1-6}$  alkyl group),  $OCHF_2$ ,  $COOR^{14}$ ,  $NH_2$ ,  $NHR^{14}$ ,  $NR^{14}R^{15}$  ( $R^{15}$  is  $C_{1-6}$  alkyl group),  $CONH_2$ ,  $CONHR^{14}$ ,  $CONR^{14}R^{15}$ ,  $COSR^{14}$ ,  $SR^{14}$ ,  $S(O)R^{14}$ ,  $S(O)_2R^{14}$ ,  $SO_3H$ ,  $SO_3R^{14}$ ,  $SO_2NH_2$ ,  $SO_2NHR^{14}$ ,  $SO_2NR^{14}R^{15}$ , CN and phenyloxy group};

$R^a$  and  $R^b$  are independently of each other  $C_{1-6}$  alkyl group,  $-L^2-NR^{16}R^{17}$  { $R^{16}$  and  $R^{17}$  are independently of each other hydrogen atom,  $C_{1-6}$  alkyl group (the  $C_{1-6}$  alkyl group may be substituted with phenyl group (the phenyl group may be substituted with  $C_{1-6}$  alkoxy group or halogen atom)) or phenyl group (the phenyl group may be substituted with  $C_{1-6}$  alkoxy group or halogen atom)},  $L^2$  is  $C_{2-6}$  alkylene group (the  $C_{2-6}$  alkylene group may be arbitrarily substituted with  $C_{1-3}$  alkyl group or phenyl group (the phenyl group may be arbitrarily substituted with halogen atom,  $C_{1-3}$  alkyl group or  $C_{1-3}$  alkoxy group))),  $CH_2O-L^2-NR^{16}R^{17}$ ,  $Ar^1$  ( $Ar^1$  is phenyl group (the phenyl group may be arbitrarily substituted with halogen atom,  $C_{1-3}$  alkyl group or  $C_{1-3}$  alkoxy group)),  $CH=CHAr^1$ ,  $CH_2CH(OH)Ar^1$ ,  $CHO$ ,  $CN$ ,  $CH_2OH$ ,  $CHOR^{16}$ ,  $-L^2-N(CH_2CH_2)_2NR^{16}$  or  $NR^{16}R^{17}$ ;

Y is  $C_{1-20}$  alkyl group {the  $C_{1-20}$  alkyl group may be substituted with phenyl group (the phenyl group may be substituted with  $C_{1-6}$  alkoxy group or halogen atom),  $C_{2-6}$  alkenyl group or  $C_{2-6}$  alkynyl group (the  $C_{2-6}$  alkenyl group and  $C_{2-6}$  alkynyl group may be substituted with phenyl group (the phenyl group may be substituted with  $C_{1-6}$  alkoxy group or halogen atom))},  $-L^3-NR^{18}R^{19}$  { $R^{18}$  and  $R^{19}$  are independently of each other


C<sub>1-6</sub> alkyl group (the C<sub>1-6</sub> alkyl group may be substituted with phenyl group (the phenyl group may be substituted with C<sub>1-6</sub> alkoxy group or halogen atom)) or phenyl group (the phenyl group may be substituted with C<sub>1-6</sub> alkoxy group or halogen atom), L<sup>3</sup> is C<sub>2-6</sub> alkylene group (the C<sub>2-6</sub> alkylene group may be arbitrarily substituted with C<sub>1-3</sub> alkyl group or phenyl group (the phenyl group may be arbitrarily substituted with halogen atom, C<sub>1-3</sub> alkyl group or C<sub>1-3</sub> alkoxy group))),



(wherein o and p are independently of each other 3 or 4, q is 1, 2 or 3), and

\* is absolute configuration of R.]

2. (Original) The T-type calcium channel blocker that is optically active 1,4-dihydropyridine compound, a pharmaceutically acceptable salt thereof or a solvate thereof, according to claim 1, wherein Y is -L<sup>3</sup>-NR<sup>18</sup>R<sup>19</sup> {R<sup>18</sup> and R<sup>19</sup> are independently of each other C<sub>1-6</sub> alkyl group (the C<sub>1-6</sub> alkyl group may be substituted with phenyl group (the phenyl group may be substituted with C<sub>1-6</sub> alkoxy group or halogen atom)) or phenyl group (the phenyl group may be substituted with C<sub>1-6</sub> alkoxy group or halogen atom), L<sup>3</sup> is C<sub>2-6</sub> alkylene group (the C<sub>2-6</sub> alkylene group may be arbitrarily substituted with C<sub>1-3</sub> alkyl group or phenyl group (the phenyl group may be arbitrarily substituted with halogen atom, C<sub>1-3</sub> alkyl group or C<sub>1-3</sub> alkoxy group))),



(wherein o and p are independently of each other 3 or 4, q is 1, 2 or 3), and

$R^a$  is  $C_{1-6}$  alkyl group.

3. (Original) The T-type calcium channel blocker that is optically active 1,4-dihydropyridine compound, a pharmaceutically acceptable salt thereof or a solvate thereof, according to claim 2, wherein  $R^b$  is  $C_{1-6}$  alkyl group, CN or  $NH_2$ .

4. (Original) The T-type calcium channel blocker that is optically active 1,4-dihydropyridine compound, a pharmaceutically acceptable salt thereof or a solvate thereof, according to claim 1, wherein Y is  $C_{1-20}$  alkyl group {the  $C_{1-20}$  alkyl group may be substituted with phenyl group (the phenyl group may be substituted with  $C_{1-6}$  alkoxy group or halogen atom),  $C_{2-6}$  alkenyl group or  $C_{2-6}$  alkynyl group (the  $C_{2-6}$  alkenyl group and  $C_{2-6}$  alkynyl group may be substituted with phenyl group (the phenyl group may be substituted with  $C_{1-6}$  alkoxy group or halogen atom))},

$R^b$  is  $-L^2-NR^{16}R^{17}$  { $R^{16}$  and  $R^{17}$  are independently of each other hydrogen atom,  $C_{1-6}$  alkyl group (the  $C_{1-6}$  alkyl group may be substituted with phenyl group (the phenyl group may be substituted with  $C_{1-6}$  alkoxy group or halogen atom)) or phenyl group (the phenyl group may be substituted with  $C_{1-6}$  alkoxy group or halogen atom)},  $L^2$  is  $C_{2-6}$  alkylene group (the  $C_{2-6}$  alkylene group may be arbitrarily substituted with  $C_{1-3}$  alkyl group or phenyl group (the

phenyl group may be arbitrarily substituted with halogen atom, C<sub>1-3</sub> alkyl group or C<sub>1-3</sub> alkoxy group))), CH<sub>2</sub>O-L<sup>2</sup>-NR<sup>16</sup>R<sup>17</sup> or -L<sup>2</sup>-N(CH<sub>2</sub>CH<sub>2</sub>)<sub>2</sub>NR<sup>16</sup>, and R<sup>a</sup> is C<sub>1-6</sub> alkyl group.

5. (Currently Amended) The T-type calcium channel blocker that is optically active 1,4-dihydropyridine compound, a pharmaceutically acceptable salt thereof or a solvate thereof, according to claim 2, ~~3 or 4~~, wherein R<sup>1</sup> and R<sup>2</sup> are independently of each other C<sub>1-6</sub> alkyl group {the C<sub>1-6</sub> alkyl group may be substituted with phenyl group (the phenyl group may be substituted with C<sub>1-6</sub> alkoxy group or halogen atom), C<sub>2-6</sub> alkenyl group or C<sub>2-6</sub> alkynyl group (the C<sub>2-6</sub> alkenyl group and C<sub>2-6</sub> alkynyl group may be substituted with phenyl group (the phenyl group may be substituted with C<sub>1-6</sub> alkoxy group or halogen atom))}, or R<sup>1</sup> and R<sup>2</sup> together form -CR<sup>5</sup>R<sup>6</sup>-CR<sup>7</sup>R<sup>8</sup>-, -CR<sup>5</sup>R<sup>6</sup>-CR<sup>7</sup>R<sup>8</sup>-CR<sup>9</sup>R<sup>10</sup>- or -CR<sup>5</sup>R<sup>6</sup>-CR<sup>7</sup>R<sup>8</sup>-CR<sup>9</sup>R<sup>10</sup>-CR<sup>11</sup>R<sup>12</sup>- (R<sup>5</sup> to R<sup>12</sup> are independently of each other hydrogen atom or C<sub>1-6</sub> alkyl group, or any two of them together with the carbon atom bonding them may form 5-, 6- or 7-membered ring); X<sup>1</sup> and X<sup>2</sup> are both O.

6. (Original) The T-type calcium channel blocker that is optically active 1,4-dihydropyridine compound, a pharmaceutically acceptable salt thereof or a solvate thereof, according to claim 5, wherein Ar is phenyl, 3-nitrophenyl, 2-nitrophenyl, 3-chlorophenyl, 2-chlorophenyl, 3-methoxyphenyl, 2-methoxyphenyl, 2-trifluoromethylphenyl, 2-trifluoromethylphenyl or 2,3-dichlorophenyl.

7. (Original) The T-type calcium channel blocker that is optically active 1,4-dihydropyridine compound, a pharmaceutically acceptable salt thereof or a solvate thereof, according to claim 6, wherein R<sup>1</sup> and R<sup>2</sup> together form -CH<sub>2</sub>-C(CH<sub>3</sub>)<sub>2</sub>-CH<sub>2</sub>-, X<sup>1</sup> and X<sup>2</sup> are

both O, Ar is 3-nitrophenyl, R<sup>a</sup> and R<sup>b</sup> are both methyl, and Y is 2-[benzyl(phenyl)amino]ethyl.

8. (Currently Amended) A pharmaceutical containing the T-type calcium channel blocker according to ~~any one of claims 1 to 7~~claim 1.

9. (Currently Amended) A therapeutic or preventive agent against a disease for which T-type calcium channel blocking action is effective, containing the T-type calcium channel blocker according to ~~any one of claims 1 to 7~~claim 1.

10. (Currently Amended) A therapeutic or preventive agent against hypercardia, containing the T-type calcium channel blocker according to ~~any one of claims 1 to 7~~claim 1.

11. (Currently Amended) A therapeutic or preventive agent against heart failure, containing the T-type calcium channel blocker according to ~~any one of claims 1 to 7~~claim 1.

12. (Currently Amended) A therapeutic or preventive agent against cardiomyopathy, containing the T-type calcium channel blocker according to ~~any one of claims 1 to 7~~claim 1.

13. (Currently Amended) A therapeutic or preventive agent against atrial fibrillation, containing the T-type calcium channel blocker according to ~~any one of claims 1 to 7~~claim 1.

14. (Currently Amended) A therapeutic or preventive agent against tachycardia-arrhythmia, containing the T-type calcium channel blocker according to ~~any one of claims 1~~

~~to~~ claim 1.

15. (Currently Amended) A therapeutic or preventive agent against arterial sclerosis, containing the T-type calcium channel blocker according to ~~any one of claims 1 to 7~~ claim 1.

16. (Currently Amended) A therapeutic or preventive agent against nephritis, containing the T-type calcium channel blocker according to ~~any one of claims 1 to 7~~ claim 1.

17. (Currently Amended) A therapeutic or preventive agent against nephropathy, containing the T-type calcium channel blocker according to ~~any one of claims 1 to 7~~ claim 1.

18. (Currently Amended) A therapeutic or preventive agent against renal disorder, containing the T-type calcium channel blocker according to ~~any one of claims 1 to 7~~ claim 1.

19. (Currently Amended) A therapeutic or preventive agent against renal insufficiency, containing the T-type calcium channel blocker according to ~~any one of claims 1 to 7~~ claim 1.

20. (Currently Amended) A therapeutic or preventive agent against edema, containing the T-type calcium channel blocker according to ~~any one of claims 1 to 7~~ claim 1.

21. (Currently Amended) A therapeutic or preventive agent against inflammation, containing the T-type calcium channel blocker according to ~~any one of claims 1 to 7~~ claim 1.

22. (Currently Amended) A therapeutic or preventive agent against hyperaldosteronism, containing the T-type calcium channel blocker according to ~~any one of claims 1 to 7~~claim 1.

23. (Currently Amended) A therapeutic or preventive agent against neurogenic pain, containing the T-type calcium channel blocker according to ~~any one of claims 1 to 7~~claim 1.

24. (Currently Amended) A therapeutic or preventive agent against epilepsy, containing the T-type calcium channel blocker according to ~~any one of claims 1 to 7~~claim 1.